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Background: Healthcare-associated infections (HAIs) 
pose a major challenge to health systems. Burden 
of disease estimations in disability-adjusted life 
years (DALYs) are useful for comparing and rank-
ing HAIs. Aim: To estimate the number of five com-
mon HAIs, their attributable number of deaths and 
burden for Germany. Methods: We developed a new 
method and R package that builds on the approach 
used by the Burden of Communicable Diseases in 
Europe (BCoDE) project to estimate the burden of HAIs 
for individual countries. We used data on healthcare-
associated Clostridioides difficile infection, healthcare-
associated pneumonia, healthcare-associated primary 
bloodstream infection, healthcare-associated urinary 
tract infection and surgical-site infection, which were 
collected during the point prevalence survey of HAIs in 
European acute-care hospitals between 2011 and 2012. 
Results: We estimated 478,222 (95% uncertainty inter-
val (UI): 421,350–537,787) cases for Germany, result-
ing in 16,245 (95% UI: 10,863–22,756) attributable 
deaths and 248,920 (95% UI: 178,693–336,239) DALYs. 
Despite the fact that Germany has a relatively low hos-
pital prevalence of HAIs compared with the European 
Union/European Economic Area (EU/EEA) average, 
the burden of HAIs in Germany (308.2 DALYs/100,000 
population; 95% UI: 221.2–416.3) was higher than the 
EU/EEA average (290.0 DALYs/100,000 population; 
95% UI: 214.9–376.9). Our methodology is applicable 
to other countries in or outside of the EU/EEA. An R 
package is available from https://CRAN.R-project.org/
package=BHAI.
Conclusion: This is the first study to estimate the bur-
den of HAIs in DALYs for Germany. The large number of 
hospital beds may be a contributing factor for a rela-
tively high burden of HAIs in Germany. Further focus 
on infection prevention control, paired with reduction 
of avoidable hospital stays, is needed to reduce the 
burden of HAIs in Germany.
Introduction
Healthcare-associated infections (HAIs) are associ-
ated with an increased risk in morbidity, mortality 
and excess healthcare costs. It is estimated that 20 to 
30% of HAIs in Germany could be preventable primar-
ily through improved adherence to hygiene recommen-
dations and optimisation of procedures [1]. Increasing 
adherence and changing behaviour of clinical person-
nel is resource-intensive, and resources for prevention 
are limited [2]. Estimates of health burden of HAIs are 
therefore needed to assess their relevance compared 
with other communicable diseases and help with 
evidence-based prioritisation. Since a patient with a 
HAI experiences this alongside the primary reason for 
being in a healthcare setting, attributing complications 
and death to a HAI is particularly challenging.
The European Centre for Disease Prevention and 
Control (ECDC) published the first estimates of the 
health burden attributable to HAIs in the European 
Union and European Economic Area (EU/EEA) in 2016 
[3]. It used the same incidence-based approach 
as the ECDC Burden of Communicable Diseases in 
2 www.eurosurveillance.org
Europe (BCoDE) project to estimate the number of 
disability-adjusted life years (DALYs) due to HAIs. The 
estimates were based on data from the ECDC point 
prevalence survey (PPS) of HAIs and antimicrobial use 
in European acute care hospitals between 2011 and 
2012 [4–6]. DALYs are a comprehensive measure to 
rank the burden of diseases and this way of ranking is 
more valuable than ranking only on incidence or preva-
lence. The BCoDE tool assists in calculating the num-
ber of DALYs specifically for a number of communicable 
diseases, including HAIs [7].
In this study, we used a new adapted methodol-
ogy to estimate the incidence of HAIs, attributable 
deaths and DALYs in 2011 in Germany for five common 
types of HAIs: healthcare-associated  Clostridioides 
difficile  infection (CDI), healthcare-associated 
pneumonia (HAP), healthcare-associated primary 
bloodstream infection (BSI), healthcare-associated 
urinary tract infection (UTI) and surgical site 
infection (SSI). In addition, we compared our estimates 
of the burden of HAIs in Germany with estimates for the 
EU/EEA.
Methods
Study population and study design
The German PPS data used in this study were collected 
in 2011 as part of the ECDC PPS, which was conducted 
between 2011 and 2012 in 29 EU/EEA countries and 
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Type of HAI    No. HAIs
3. From hospital incidence
to population incidence
No. HAIsNo. HAIsNo. DALYs
25,000 05,00015,000 25,0000 5,000 15,000 40,000 020,000 0 20,000 40,000
No. DALYs
BHAI: Burden of Healthcare-Associated Infections; BSI: healthcare-associated primary bloodstream infection; CDI: healthcare-associated 
Clostridioides difficile infection; DALY: disability-adjusted life year; HAI: healthcare-associated infection; HAP: healthcare-associated 
pneumonia; No.: Number of; PPS: point prevalence survey; SSI: surgical site infection; UTI: healthcare-associated urinary tract infection; 
YLD: years lived with disability; YLL: years of life lost.
a Age in years.
The error bars indicate the 95% uncertainty intervals.
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Croatia, which has since become the 28th  EU Member 
State [6]. Three datasets were available for our 
analyses:
(i) The representative German PPS sample consists 
of 46 hospitals, randomly selected from a list of all 
German hospitals stratified by hospital size [6]. The 
sample includes 9,626 patients in total.
(ii) A larger German convenience sample of the same 
PPS, which is not representative by hospital size, con-
sists of 132 hospitals and 41,539 patients.
(iii) For comparison, we used the ECDC PPS sample, 
which includes 273,753 patients from 1,149 hospitals 
in 29 EU/EEA countries in 2011 and 2012 and Croatia 
[6]. We estimated the burden of HAIs for the ECDC 
PPS sample using the original data and our adapted 
methodology, which is implemented in the Burden of 
Healthcare-associated Infections (BHAI) R package (see 
below for more details).
The types of HAIs selected for this study were as 
described by Cassini et al. [3]. The selection was based 
on prevalence, availability of data and evidence from 
systematic reviews. HAIs were defined according to 
EU case definitions [8], with the exception of CDIs, for 
which we selected a syndrome-based approach.
Outcome measure
DALYs are a composite measure of years lived with dis-
ability (YLDs) and years of life lost (YLLs) accounting for 
incidence, severity and mortality of the disease simul-
taneously. This approach enables ranking and compa-
rability of the health burden of different types of HAIs 
in one metric.
Outcome trees with transition probabilities
Disease models or outcome trees illustrate progression 
pathways of HAIs over time, starting with acute infec-
tion and ending with either recovery, permanent disa-
bility, or death. To take into account all possible health 
consequences of HAIs, outcome trees were developed 
based on 13 systematic reviews of the literature [9,10]. 
Attributable transition probabilities were extracted 
from the literature to avoid overestimation of the health 
burden due to comorbidities, which is a particular risk 
in patients with an HAI. Health outcomes were related 
to each other by a transition probability and each out-
come included a duration and a disability weight [9,11]. 
We used the same outcome trees with transition prob-
abilities and disability weights, which were used by 
Cassini et al.. Detailed descriptions of the outcome 
trees can be found in the supplement of Cassini et al. 
or within the ECDC BCoDE toolkit, in which the disease 
model parameters are described in detail [3,7]. The 
systematic reviews and results of meta-analyses were 
published in a separate document [9].
Workflow of the Burden of Healthcare-
Associated Infections (BHAI) methodology
Our approach was implemented by the BHAI R package, 
which performs a predefined number (default: 1,000) of 
Monte Carlo simulations (Figure 1).
Step 1: estimation of hospital prevalence of healthcare-
associated infections
For each type of HAI, hospital prevalence (P) was esti-
mated using the observed number of patients with 
an HAI and the total number of patients in the PPS. 
Prevalence was calculated separately for the German 
representative and convenience samples. Uncertainties 
were taken into account by sampling from a mixture 
Table 1
Annual burden of five types of healthcare-associated infections, German point prevalence survey sample, Germany, 2011
Type 
of HAI Sample
Number of HAIs 
 
Point estimatea (95% UI)
Number of attributable 
deaths 
 
Point estimatea (95% UI)
Number of DALYs 
 
Point estimatea (95% UI)
Number of YLLs 
 
Point estimatea (95% UI)
Number of YLDs 
 
Point estimatea (95% UI)
HAP German PPS 106,586 (83,618–137,476) 3,968 (1,107–8,164) 69,508 (34,042–117,232) 41,306 (11,475–84,483) 27,539 (16,528–42,824)
SSI German PPS 93,222 (75,369–114,241) 2,328 (1,888–2,882) 28,842 (23,313–35,303) 28,376 (22,983–34,714) 452 (352–580)
BSI German PPS 26,976 (16,520–42,252) 3,905 (2,004–6,987) 58,350 (30,940–104,227) 49,578 (25,499–90,816) 8,787 (4,463–16,609)
UTI German PPS 214,150 (175,086–253,524) 3,664 (1,462–7,533) 66,701 (27,890–128,543) 44,871 (18,043–92,915) 20,243 (8,095–40,522)
CDI German PPS 36,002 (25,108–49,934) 1,917 (112–4,547) 20,890 (2,023–49,443) 19,937 (1,166–47,973) 977 (172–2,125)
All German PPS 478,222 (421,350–537,787) 16,245 (10,863–22,756) 248,920 (178,693–336,239) 190,245 (131,301–264,573) 59,076 (40,263–84,578)
BSI: healthcare-associated primary bloodstream infection; CDI: healthcare-associated Clostridioides difficile infection); DALY: disability-
adjusted life year; HAI: healthcare-associated infection; HAP: healthcare-associated pneumonia; PPS: point prevalence survey; SSI: surgical 
site infection; UI: uncertainty interval; UTI: healthcare-associated urinary tract infection; YLD: years lived with disability; YLL: years of life 
lost.
a This is the median.
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of two beta distributions, which form the exact mid-
P-Clopper–Pearson confidence interval (CI) for pro-
portions. The use of this mixed distribution gives 
uncertainty intervals (2.5% and 97.5% quantiles) that 
accurately reflect exact CIs.
Step 2: estimation of hospital incidence of healthcare-
associated infections using prevalence
We estimated hospital incidence (I) from P for each type 
of HAI using a modification of the Rhame−Sudderth 
formula: I = P × LA/LOI, where LA is the mean length of 
stay and LOI is the length of infection [12]. The aver-
age LA of all patients in the survey was calculated from 
data of participating hospitals, based on the number 
of discharges and patient days in the previous year 
[13]. The modified Rhame−Sudderth formula defines 
LOI as the total time of infection. Often, only the time 
from infection onset until the date of survey (LOIpps) is 
collected. Estimators of LOI that have been used in 
the past are the median or mean of LOIpps, which are 
approximations for the true LOI. We used the Grenander 
estimator which was employed in 2018 to estimate the 
number of HAIs in the EU/EEA [14,15]. In this method, 
the distributions of LOIpps were estimated from the PPS 
data assuming monotonicity. This assumption is jus-
tified by the timeline of occupancy of a hypothetical 
bed: There will always be more patients on the first 
day than on the second day of hospitalisation, and 
more on the second day than the third day, etc. The 
average proportion of patients with a HAI on the day 
of the PPS was derived from the following distribution: 
Probability(LOIpps = 1). The expected LOI of a HAI was 
then estimated as 1/Probability(LOIpps = 1). One caveat 
of this method is that it requires a large sample size. 
However, Willrich et al. showed that the mean, which is 
biased but more robust with small samples, performed 
well in most applications [14]. Our methodology there-
fore used a weighted sum of the mean of LOIpps and the 
Grenander estimator using the sigmoid function. This 
allowed the influence of the Grenander estimator to 
become larger, and therefore the estimates were more 
accurate with larger sample sizes. Simulations that 
analyse the robustness of the LOI estimates for dif-
ferent sample sizes using this new approach are sum-
marised in  Supplementary Figure S1. BHAI takes into 
account the uncertainty about the LOI estimate using 
bootstraps in each Monte Carlo simulation. The larger 
German PPS convenience sample was used for more 
reliable estimation of LOIs. The LOIs used for computa-
tions are displayed in Supplementary Figure S2.
Step 3: from hospital incidence to population incidence 
of healthcare-associated infections
Hospital incidences of HAIs per patient were extrapo-
lated to the whole population by multiplying with the 
number of hospital discharges in Germany. The popu-
lation data and number of hospital discharges for 2011 
were obtained from the Eurostat database (http://
ec.europa.eu/eurostat/ ) for all countries following the 
approach of Cassini et al. [3,13].
Step 4: stratification by age and sex according to point 
prevalence survey age distribution
After estimating the total annual number of cases in the 
previous steps, BHAI was used to estimate the number 
of attributable deaths and DALYs. For DALY calcula-
tions, HAIs distributed according to age and sex were 
needed to account for different life expectancies. For 
each type of HAI, the age and sex distributions were 
obtained from the ECDC PPS. With smaller country-
wide PPS, the stratified number of cases may exhibit 
many empty strata (without cases). We used Bayesian 
analysis to include prior knowledge about the distribu-
tion and combined this information with the evidence 
from the observed data in a posterior distribution of 
the true parameters.
The posterior distribution was a multinomial likelihood 
with a Dirichlet prior distribution, which is parameter-
ised by prior weights. The estimation of the health 
burden from the German PPS sample was conducted 
by applying the number of cases from the German con-
venience sample as prior weights. This distribution 
also contained empty strata, although fewer than in 
the German PPS sample. Since all prior weights had to 
be > 0, the BHAI R package added a small pseudocount 
to all strata: 0.001 × sum(prior weights). In each Monte 
Figure 2
Annual number of healthcare-associated infections plotted 
against the annual number of attributable deaths for five 






































BSI: healthcare-associated primary bloodstream infection; 
CDI: healthcare-associated Clostridioides difficile infection; 
DALY: disability-adjusted life year; HAI: healthcare-associated 
infection; HAP: healthcare-associated pneumonia; SSI: surgical 
site infection; UTI: healthcare-associated urinary tract infection.
a Data are based on the 2011 German point prevalence study 
sample.
The diameter of the bubbles is proportional to the annual numbers 
of DALYs, Germany, 2011.
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Carlo simulation, a sample was drawn from the poste-
rior distribution, which incorporated uncertainty about 
the age and sex distribution. The sampled age and sex 
probability distribution was then multiplied with the 
overall annual number of cases to calculate the strati-
fied number of cases for each type of HAI.
Step 5: adjusting for different life expectancies
The McCabe score, documented in the ECDC PPS 
between 2011 and 2012, gave a reference point for the 
life expectancy of a patient according to severity of 
underlying disease. It allowed patients to be stratified 
in three groups according to whether the underlying 
disease was (i) non-fatal (normal life expectancy), (ii) 
ultimately fatal (average expected life expectancy 
of 3 years), or (iii) rapidly fatal (average expected life 
expectancy of 0.5 years). German PPS data were col-
lected using the unit-based (‘light’) protocol of the 
ECDC PPS, for which McCabe scores are not recorded 
[6]. We applied the McCabe score distribution of the 
ECDC PPS to Germany (i.e. cumulative data from all 
countries that collected McCabe scores with the stand-
ard protocol), assuming that the McCabe score distri-
bution in Germany would be comparable to that of the 
entire EU/EEA. In the BHAI R package, we calculated a 
probability distribution of McCabe scores for each HAI, 
age and sex stratum and distributed cases by multipli-
cation with the number of estimated cases in each sim-
ulation. In each Monte Carlo simulation, parameters of 
disease outcome trees, i.e. disability weights, dura-
tions and transition probabilities, were sampled for 
the whole population. The number of fatalities attribut-
able to each type of HAI was calculated by multiplying 
the number of cases with the probability of death. The 
number of DALYs was calculated with respect to the 
remaining life expectancy in each stratum.
Validity of estimates obtained with the Burden 
of Healthcare-Associated Infections (BHAI) 
method
We simulated ECDC PPS data ranging from 1,000 to 
200,000 surveyed patients (the latter being approxi-
mately equal to the size of the ECDC PPS sample). This 
allowed us to compare the sampling approach imple-
mented in the BHAI R package with the approach of the 
previous burden estimation using the BCoDE toolkit 
[3,7]. In each simulation, given the number of surveyed 
patients, the prevalence for each type of HAI from the 
overall ECDC PPS sample was used to simulate the 
number of cases of each type of HAI. These were then 
randomly distributed to strata according to the age, sex 
and McCabe distributions of the ECDC PPS. The length 
of the HAIs was sub-sampled according to the number 
of HAIs in each simulation, while the mean LA was kept 
fixed to the estimate from the full sample. In order to 
evaluate the effect of the sample size on the estima-
tion, the results from the simulated data were then 
compared with the results from the ECDC PPS sample.
Availability
Our method was implemented by the BHAI R package, 
which is freely available from  https://cran.r-project.
org/  and as a Supplement to this paper (Supplement 
S1). The data and analysis code used for calculating the 
German and EU/EEA burden of HAIs are attached to the 
package, which can be used to reproduce the analysis 
and the results described in this study.
Table 2
Annual burden per 100,000 population of five types of healthcare-associated infections, German PPS sample, German 



































German PPS 132.0 (103.5–170.2) 265.1 (216.8–313.9) 33.4 (20.5–52.3) 115.4 (93.3–141.4) 44.6 (31.1–61.8) 592.1 (521.7–665.8)
German 
convenience 162.3 (137.5–190.7) 228.7 (200–260.7) 52.7 (42–66.9) 146.9 (126.5–167.8) 44.5 (35.6–55.4) 636.1 (586.7–689.2)
ECDC PPS (EU/




German PPS 4.9 (1.4–10.1) 4.5 (1.8–9.3) 4.8 (2.5–8.7) 2.9 (2.3–3.6) 2.4 (0.1–5.6) 20.1 (13.4–28.2)
German 
convenience 6.1 (1.4–11.7) 3.9 (1.6–8) 7.9 (4.7–11.8) 3.7 (3.2–4.2) 2.5 (0.1–5.3) 24.4 (17.2–32.6)
ECDC PPS (EU/
EEA) 5.3 (1.3–10.2) 3.0 (1.2–5.9) 3.3 (2.1–4.6) 2.6 (2.4–2.7) 0.9 (0–1.8) 15.3 (10.2–21.2)
DALYs per 
100,000
German PPS 86.1 (42.1–145.1) 82.6 (34.5–159.2) 72.2 (38.3–129) 35.7 (28.9–43.7) 25.9 (2.5–61.2) 308.2 (221.2–416.3)
German 
convenience 103.4 (51.5–166.5) 69.5 (29.9–127.7) 113.5 (72.2–166) 45.0 (38.8–51.3) 26.5 (2.5–55.6) 359.3 (266.6–461.5)
ECDC PPS (EU/
EEA) 109.8 (55.3–170.5) 57.1 (24.3–102.9) 76.2 (52.6–104.8) 35.1 (33.3–36.8) 10.0 (0.9–19.2) 290.0 (214.9–376.9)
BSI: healthcare-associated primary bloodstream infection; CDI: healthcare-associated Clostridioides difficile infection; DALY: disability-
adjusted life year; ECDC: European Centre for Disease Prevention and Control; EU/EEA: European Union/European Economic Area; HAP: 
healthcare-associated pneumonia; PPS: point prevalence survey; SSI: surgical site infection; UTI: healthcare-associated urinary tract 
infection.
a This is the median.
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Ethical statement
This study was based on health information collected 
and published within the ECDC PPS and did not require 
informed consent from participants. Reported infec-
tious disease data were provided in aggregated for-
mat by specific age and sex strata, without personal 
identifiers.
Results 
Burden of healthcare-associated infections in 
Germany
Using German PPS data from 2011, we estimated 
that there were 478,222 (95% UI: 421,350–537,787) 
new cases of the selected types of HAIs, and 
16,245 (95% UI: 10,863–22,756) attributable deaths 
in Germany in that year (Table 1). The health bur-
den of acute HAIs and sequelae amounted to a 
median of 248,920 (95% UI: 178,693–336,239) DALYs, 
59,076 (95% UI: 40,263–84,578) YLDs and 
190,245 (95% UI: 131,301–264,573) YLLs per year. 
Note that the sum of the median YLDs and YLLs does 
not exactly equal the median DALYs. This is because 
the sum of the median of two distributions (i.e. YLDs 
and YLLs for all 1,000 simulations) is not necessarily 
equal to the median of the sum of the distributions (i.e. 
DALYs calculated as YLD + YLL for each simulation). 
The relationship between incidence, mortality and 
DALYs is illustrated in  Figure 2, which gives detailed 
information about the different impacts of HAIs on 
population health. HAP and BSI accounted for 51% 
(127,858 DALYs/248,920 DALYs) of the burden of HAIs, 
but accounted for only 28% (133,562 cases/478,222 
cases) of the estimated number of HAIs (Figure 2). 
UTIs accounted for 45% (214,150 cases/478,222 cases) 
of the cases, but for 27% (66,701 DALYs/248,920 
DALYs) of DALYs. Estimates of the length of the HAIs 
varied from 9 to 15 days depending on the type of 
HAI (Supplementary Figure S2).
From the larger German convenience sam-
ple, we estimated that there were 
513,729 (95% UI: 473,840–556,654) HAIs per year, and 
19,672 (95% UI: 13,921–26,310) attributable deaths, 
leading to 290,228 (95% UI: 215,305–372,734) DALYs, 
65,988 (95% UI: 46,856–89,194) YLDs and 
224,939 (95% UI: 160,973–298,122) YLLs (Supplementary 
Table S1, Supplementary Figure S3 and S4) in 2011.
Figure 3
Annual burden of five types of healthcare-associated infections with (A) attributable deaths per 100,000 population and (B) 











































ECDC PPS (EU/EEA):German PPS:
BSI: healthcare-associated primary bloodstream infection; CDI: healthcare-associated Clostridioides difficile infection; DALY: disability-
adjusted life year; ECDC: European Centre for Disease Control and Prevention; EU/EEA: European Union/European Economic Area; HAI: 
healthcare-associated infection; HAP: healthcare-associated pneumonia; PPS: point prevalence survey; SSI: surgical site infection; UI: 
uncertainty interval; UTI: healthcare-associated urinary tract infection; YLD: years lived with disability; YLL: years of life lost.
For all five HAIs, attributable deaths amount to 20.1 per 100,000 population (95% UI: 13.4–28.2) and DALYs to 308.2  per 100,000 population 
(95% UI: 221.2–416.3).
The error bars indicate the 95% UI.
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In both the German convenience and the representa-
tive PPS samples, 4.1%  of patients in hospital (394 
patients with HAI/9,626 patients and 1,688 patients 
with HAI/41,539 patients for each type of sample 
respectively) had at least one of the five types of HAIs. 
The difference in disease burden found between the 
convenience and PPS samples was mainly due to an 
increased prevalence of HAPs (1.0%; 424 patients with 
HAP/41,539 patients) and BSIs (0.34%; 142 patients 
with BSI/41,539 patients) in the German convenience 
sample.
Comparison to other communicable diseases
From the German PPS sample, we estimated that 
the total burden of the five HAIs in Germany was 
308.2 DALYs per 100,000 population. In contrast, a 
previous study using the BCoDE methodology esti-
mated that the burden of four other communicable 
diseases (influenza,  Salmonella  spp., hepatitis B and 
measles) in Germany was only 39.4 DALYs per 100,000 
population (Supplementary Table S2) [16].
Comparison to the European Union/European 
Economic Area
From the ECDC PPS conducted between 2011 and 2012, 
we estimated the burden of HAIs for the whole EU/EEA 
using the adapted BHAI method. We found that there 
were 2,365,466 (95% UI: 2,306,018–2,427,774) HAIs, 
77,483 (95% UI: 51,502–106,982) attributable deaths 
and 1,465,822 (95% UI: 1,086,252–1,905,451) DALYs in 
the EU/EEA (Supplementary Table S3).
Rates per 100,000 population are presented in  Table 
2  and allow for comparison of the three different 
samples. The incidence of HAIs in Germany (German PPS 
representative sample) was 1.27 (95% UI: 1.14–1.43) 
times higher than the EU/EEA (ECDC PPS sample). The 
estimated number of attributable deaths per 100,000 
population and DALYs per 100,000 population were 
1.29 (95% UI: 0.78–2.18) and 1.06 (95% UI: 0.68–1.67) 
times higher in Germany (German PPS representative 
sample) than in the EU/EEA. This difference was 
even larger when comparing rates obtained from the 
German convenience sample with EU/EEA estimates. 
There was a 1.36 (95% UI: 1.25–1.47) higher incidence 
of HAIs, 1.58 (95% UI: 0.95–2.66) higher attributable 
mortality and 1.24 (95% UI: 0.83–1.84) higher DALY 
rate in Germany than in the EU/EEA. Comparisons of 
the rates obtained for Germany (German representa-
tive and convenience PPS samples) to the EU/EEA 
estimates (ECDC PPS sample) are given in  Figures 
3 and 4 and in Supplementary Figures S5 and S6.
Burden of Healthcare-Associated Infections 
(BHAI) methodology and R package
The new methodology for the estimation of HAIs pre-
sented in this study was implemented in the R pack-
age BHAI (openly available from  https://cran.r-project.
org/). It was evaluated using a simulated PPS with sam-
ple sizes ranging from 1,000–200,000. This evaluation 
demonstrates the usability of BHAI for the estimation 
of the burden of HAIs for large and small PPS sam-
ples (Supplementary Figure S7).
Discussion
In this study, we estimated the burden of HAIs in 
Germany expressed in DALYs for the first time, based 
on point prevalence data from 2011. By considering 
incidence and severity of the disease simultaneously, 
we provided a more comprehensive view on the bur-
den of HAIs than previously available. This allowed for 
comparing and ranking the burden of HAIs and other 
diseases in Germany.
The annual number of HAIs in Germany was previously 
estimated between 400,000–600,000 cases and 
10,000–15,000 attributable deaths per year. These 
estimates were based on data from the German PPS 
studies (NIDEP-1) from 1994 [17,18]. In the ECDC PPS, 
the annual number of HAIs in Germany in 2011 was esti-
mated at between 321,321–1,025,716 [6]. It is impor-
tant to note that different approaches and methods 
were used in these studies.
In this study, we estimated the numbers of cases for 
five types of HAI, associated fatalities and their health 
burden. These five types of HAI made up 79% of all 
HAIs in the ECDC PPS sample, and the numbers of 
HAIs in our study therefore do not represent the total 
number of HAIs in the population. Nevertheless, our 
estimates of the number of HAIs lie within the range of 
previous estimates, although the median estimates of 
the number of attributable deaths were higher.
In our study, BSIs had the lowest incidence of the five 
types of HAI, but was responsible for a high number 
of DALYs due to its high attributable mortality. On the 
other hand, UTI, despite its high incidence, caused a 
comparable health burden since its attributable mor-
tality was considerably lower. While, of all cases, the 
fatality rate of primary or secondary BSIs was 9–20%, 
5–20% of patients with UTI developed a secondary 
bacteraemia or urosepsis, which then led to death in 
9–20% of the cases [9,10]. These shifts in ranking 
illustrate the importance of a comprehensive approach 
such as the burden estimation based on DALYs.
The health burden of HAIs was substantially higher 
than the burden of other communicable diseases. 
For instance, the burdens of HAP (69,508 DALYs) and 
UTI (66,701 DALYs) were more than twice as large in 
comparison, and the burden of BSI (58,350 DALYs) 
was slightly less than twice as much as the burden of 
influenza (33,116 DALYs) in Germany (Supplementary 
Table S2) [16]. The burden of all five considered HAIs in 
Germany was 308.2 (95% UI: 221.2–416.3) DALYs. This 
was also higher than the burden of 31 selected infec-
tious diseases in the EU/EEA, which was estimated to 
be 273 (95% UI: 249–299) DALYs per 100,000 popula-
tion using the BCoDE methodology [19]. Comparisons 
of our estimates of the number of DALYs with those of 
the Global Burden of Disease (GBD) project must be 
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Figure 4
Total annual burden of five types of healthcare-associated infectionsa in Germany (left) and EU/EEA (right), stratified by age 
and sex and within each stratum the (A-B) total number of DALYs and (C-D) DALYs per 100,000 population, Germany, EU/
EEA, 2011–2012
A. B.
Number of DALYs (all infections) Number of DALYs (all infections) Number of  DALYs (all infections) Number of DALYs (all infections)



































































































































DALY: disability-adjusted life year; ECDC: European Centre for Disease Control and Prevention; EU/EEA: European Union/European Economic 
Area; PPS: point prevalence survey.
a The five healthcare-associated  infections comprise healthcare-associated Clostridioides difficile infection, healthcare-associated 
pneumonia, healthcare-associated primary bloodstream infection, healthcare-associated urinary tract infection and surgical site infection.
b Age in years.
The error bars indicate the 95% uncertainty intervals.
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conducted with caution, since the latter are derived 
using a prevalence-based approach [20]. In addition, 
the burden of HAIs is not presented within the GBD 
project, but is instead attributed to the underlying dis-
ease. However, a relative and rough comparison of the 
burden of HAIs with GBD estimates for other diseases 
is presented in the Supplementary Table S4 [20,21].
Comparison of Germany and the European 
Union/European Economic Area
To ensure comparability, we estimated the burden of 
the five types of HAIs in the EU/EEA with the same 
BHAI methodology and R package. The number of 
HAIs, attributable deaths and DALYs (YLDs and YLLs) 
per 100,000 population was overall higher in Germany 
than in the EU/EEA average (Table 2,  Supplementary 
Table S1 and S3, Figure 3, Supplementary Figure S5 and 
S6). Since the hospital prevalence of HAIs in Germany 
in 2011 was considerably lower than the EU/EEA aver-
age from the ECDC PPS between 2011 and 2012, we 
initially expected a lower health burden of HAIs in 
Germany [6]. However, extrapolating from the  hos-
pitalised  to the  general  population (see Methods, 
workflow step 3–5), the burden of HAIs in Germany 
was higher than the EU/EEA average. Burden of 
disease is a measure based on the general population 
and thus the number of hospitalised patients – which 
extrapolates the incidence per patient to the general 
population – is a major factor influencing the burden 
of HAIs in the general population. Germany has the 
highest number of curative beds in Europe and the 
second largest number of hospitalised patients per 
1,000 population among 34 Organisation for Economic 
Co-operation and Development (OECD) countries [22–
24]. Hygiene and infection prevention and control 
measures affect HAI occurrence among hospitalised 
patients. Germany’s relatively low prevalence among 
hospitalised patients may be partly explained by the 
generally good hygiene and infection prevention and 
control measures in German hospitals. However, since 
there are so many hospitalised patients, their effec-
tiveness may be diluted when calculating the burden 
of HAIs per general population. This becomes clear 
when comparing the incidence within the hospitalised 
population to the incidence per general population. 
In accordance with HAI prevalence, the incidence of 
HAIs within the hospitalised population was lower for 
Germany – 2.40 (95% UI: 2.12–2.70) per 100 patients – 
than for the EU/EEA – 2.83 (95% UI: 2.75–2.90) per 100 
patients (data not shown). To calculate the incidence 
per general population, the incidence per patient was 
multiplied by the number of hospital discharges and 
normalised by the total population. This results in a 
higher incidence per general population for Germany 
– 592.1 (95% UI: 521.7–665.8) per 100,000 population 
– in comparison to the incidence per general popula-
tion in the EU/EEA – 467.9 (95% UI: 456.2–480.2) per 
100,000 population. This demonstrates that the num-
ber of hospital stays is an important factor, which needs 
to be considered, alongside other measures, in order to 
reduce the burden of HAIs per general population.
The results of the German and ECDC PPS 2016 indicate 
that the HAI prevalence may have slightly decreased in 
Germany since 2011 [25]. Nevertheless, the number of 
HAIs per 100,000 was still estimated to be higher in 
Germany – 735.6 (95% CI: 452.8–1,141.9) – than the EU/
EEA estimate – 658.5 (95% CI: 437.0–957.6) [13,15].
The burden of UTIs and  C. difficile  was higher in 
Germany than the EU/EEA average, whereas the burden 
of HAP was lower in Germany (Figure 3, Supplementary 
Figure S5). This is in line with the ECDC PPS between 
2011 and 2012, where Germany was among the coun-
tries with the highest proportions of UTIs and  C. dif-
ficile infections among all HAIs within the PPS between 
2011 and 2012. Since then, efforts have been made to 
enhance antibiotic stewardship and recommendations 
have been put in place in order to prevent catheter 
associated urinary tract infections [26]. The prevalence 
of UTIs was lower in the PPS 2016 and its proportion 
among all HAIs decreased, whereas prevalence of  C. 
difficile  infections in Germany increased [27]. Further 
research is needed to analyse whether these differ-
ences point towards more or less effective strategies 
to prevent these types of HAIs.
Comparison of the BHAI and BCoDE 
methodologies
In principle, the BHAI methodology and the application 
of BCoDE for HAIs as in Cassini et al. [3] have the same 
approach: prevalence is converted to incidence per 
patient, which is then extrapolated to the population. 
Using Monte Carlo simulations, the number of HAIs is 
sampled and identical disease outcome trees are used 
to estimate the attributable burden of HAIs.
However, Cassini et al. used the median of LOIPPS  to 
estimate LOI for prevalence to incidence conversion, 
while BHAI uses a new method that was shown to be 
less prone to bias and performed more reliably in simu-
lation studies [14].
Moreover, in our analyses we found that the stratified 
sampling approach in BCoDE [3,7], may overestimate 
the number of HAIs in strata with zero cases in the 
PPS, which became more frequent with smaller sam-
ple size in the range of those in the PPS conducted for 
individual countries. To address this, BHAI samples the 
number of HAIs in each simulation on the population 
level and then distributes cases to strata by an age 
and sex distribution. We carried out simulations using 
subsamples of the full ECDC PPS dataset between 2011 
and 2012 to demonstrate that this methodological 
adjustment addressed the issue of overestimation in 
smaller samples (Methods,  Supplementary Figure S7). 
Therefore, we recommend the use of BHAI in future 
efforts to estimate the health burden of HAIs in order to 
ensure comparability, particularly at the country level.
The new sampling approach in BHAI makes applica-
tion to data collected with both the ECDC PPS patient-
based (‘standard’) and unit-based (‘light’) protocols 
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possible, whereas BCoDE can only be applied to the 
patient-based protocol. In contrast to the patient-based 
protocol, data for patients without HAIs are not col-
lected with the unit-based protocol. Data on patients 
without HAIs are needed as denominator data for 
stratification in the original BCoDE approach, but not 
required for the BHAI methodology. Nevertheless, one 
limitation of the unit-based protocol is that the mean LA 
of patients is not recorded, which meant that we had to 
use hospital denominator data from the PPS. We there-
fore calculated LA from data of participating hospitals, 
based on the number of discharges and patient days 
from the previous year. However, in the patient-based 
protocol, the mean LA is recorded for each patient. In 
this case we suggest that LA and LOI are both calcu-
lated using the method by Willrich et al., since possi-
ble biases or errors in the estimation might cancel out 
in the division of LA by LOI during the conversion from 
prevalence to incidence [14].
Limitations
The available evidence for transition probabilities 
for the outcome trees was derived from systematic 
reviews. Even though this may be the most transparent 
and unbiased approach to design outcome trees, it has 
to be noted that the underlying literature was sparse 
and of moderate to low quality [9]. With increasing evi-
dence from the literature, outcome trees will improve 
and therefore should be reevaluated in the future. 
Transition probabilities in the outcome trees represent 
the likelihood of sequelae or death attributable to an 
infection. This justifies that the burden estimation is 
based on the number of HAIs, and not on the number 
of patients. Recurrent infections for each patient are 
implicitly reflected in the transition probabilities. By 
considering HAIs independently, we do not account for 
the fact that some patients have multiple HAIs. In addi-
tion, the probability of sequelae, recovery and death 
might not be independent. But in the German PPS sam-
ple, only 7% (28 patients with two or more HAIs/394 
patients with one or more HAIs) of patients with a HAI 
had more than one HAI on the day of the PPS. Thus, 
the violation of the independence assumption likely 
results in minor overestimation.
We used the European McCabe score distribution for 
our estimation. The large number of acute care hospi-
tal beds in Germany might lead to avoidable hospital 
stays and a hospitalised patient population with less 
severe primary diseases than in other EU/EEA countries 
[22–24]. The European McCabe scores might therefore 
overestimate the severity of underlying diseases of 
German hospitalised patients. In turn, DALYs would 
be underestimated for Germany since the European 
McCabe distribution would assume lower remaining 
life expectancies.
Following the study of Cassini et al. we used hospital 
discharges of 2011 for all countries, although some 
countries conducted the PPS in 2012 [3]. In addition, 
LA was calculated using data from the previous year of 
the participating hospitals. This should not have sig-
nificantly biased our results since the variation of LA 
and the number of discharges during the study period 
was low [13].
Another possible limitation of our study is the repre-
sentativeness of the PPS data. Although hospital size 
was the only variable used for randomly sampling hos-
pitals to obtain a representative sample of German 
hospitals, case mix and specialisation also influence 
HAI prevalence. For this reason, we also estimated the 
burden of HAIs from the larger convenience sample of 
German hospitals. This analysis led to higher estimates 
of the burden of HAIs, suggesting that a high uncer-
tainty remains when estimating the burden of HAIs 
from PPS samples.
Conclusion
In summary, the open-source BHAI R package, was 
applied to German and EU/EEA data to calculate the 
burden of HAIs at country level, and is applicable to 
other countries in or outside of the EU/EEA. In Germany, 
the burden of HAIs is higher than the burden of other 
communicable diseases. Despite the fact that Germany 
has a relatively low prevalence of HAIs compared 
with other European countries, the burden of HAIs in 
Germany is higher than the EU/EEA average [6]. A prob-
able cause for the high burden of HAIs in Germany is 
the country’s large hospital patient population. It has 
been argued that the large numbers of acute care beds 
in Germany may lead to avoidable hospital stays [28]. 
Therefore, the reduction of avoidable hospital stays 
together with further focus on hygiene measures and 
infection prevention and control are important steps to 
reduce the burden of HAIs in Germany.
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